Grippferon® (Spray, Drops) Instructions for Use
ATC Code
L03AB05 (Interferon alfa-2b)
Active Substance
Interferon alfa-2b
Interferon alfa-2b (USAN adopted for use in the USA)
Clinical-Pharmacological Group
Interferon. An immunomodulatory drug with antiviral action
Pharmacotherapeutic Group
Cytokine
Pharmacological Action
A topical agent. It has immunomodulatory, anti-inflammatory, and antiviral effects.
Indications
This preparation is indicated for the management of viral respiratory infections in both pediatric and adult populations.
- For the treatment of influenza and acute respiratory viral infections (ARVI).
- For the prevention of influenza and acute respiratory viral infections (ARVI).
ICD codes
| ICD-10 code | Indication |
| J06.9 | Acute upper respiratory infection, unspecified |
| J10 | Influenza due to identified seasonal influenza virus |
| Z29.8 | Other specified prophylactic measures |
| ICD-11 code | Indication |
| 1E30 | Influenza due to identified seasonal influenza virus |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| QC05.Z | Prophylactive measures, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer intranasally for a treatment course of 5 days. The dosage is strictly age-dependent.
For treatment, instill into each nostril several times per day. For prevention, use a single dose once or twice daily. Follow the specific age-based dosing schedule provided in the full prescribing information.
Adverse Reactions
The drug is generally well-tolerated. Adverse reactions are typically mild and transient.
The most commonly reported adverse reaction is a local burning sensation in the nasal cavity upon application. Allergic reactions are possible but occur infrequently.
Contraindications
The use of this medication is prohibited in patients with known hypersensitivity to its components or other interferons.
- Hypersensitivity to interferon alfa-2b or any other ingredient of the preparation.
- History of severe allergic reactions to other interferon preparations.
- Presence of severe forms of allergic diseases.
Use in Pregnancy and Lactation
Approved for use throughout the entire period of pregnancy in accordance with the age-related dose.
Has no restrictions for use during lactation.
Pediatric Use
Used in children according to indications and in accordance with the dosage regimen.
Drug Interactions
Clinically significant pharmacokinetic interactions are not known. Exercise caution with concomitant use of other intranasal preparations.
Avoid concomitant use with intranasal decongestants (e.g., vasoconstrictors like oxymetazoline, xylometazoline), as this combination may cause excessive drying of the nasal mucosa and irritation.
Overdose
Cases of overdose with intranasal administration are unlikely and have not been reported. The systemic absorption of the active substance is negligible.
Symptoms of acute overdose are not expected. In case of suspected excessive use, discontinue the drug and manage any presenting symptoms supportively. No specific antidote exists.
Storage Conditions
Store at 2°C (36°F) to 8°C (46°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Nasal drops 10000 IU/1 ml: 10 ml bottle.
Marketing Authorization Holder
Firn M, LLC (Russia)
Dosage Form
 |
Grippferon® | Nasal drops 10000 IU/1 ml: 10 ml bottle. |
Dosage Form, Packaging, and Composition
Nasal drops in the form of a transparent, colorless or light yellow solution.
| 1 ml | |
| Human recombinant interferon alfa-2b | Not less than 10000 IU |
Excipients: disodium edetate dihydrate – 0.5 mg, sodium chloride – 4.1 mg, sodium hydrogen phosphate dodecahydrate – 11.94 mg, potassium dihydrogen phosphate – 4.54 mg, povidone-8 thousand – 10 mg, macrogol 4000 – 100 mg, purified water – up to 1 ml.
10 ml – plastic bottles (1) with a dropper dispenser – cardboard boxes.
10 ml – polymer bottles (1) with a dosing nozzle – cardboard boxes.
Metered-dose nasal spray 500 IU/1 dose: 10 ml bottle with dosing device
Marketing Authorization Holder
Firn M, LLC (Russia)
Dosage Form
|
Grippferon® | Metered-dose nasal spray 500 IU/1 dose: 10 ml bottle with dosing device |
Dosage Form, Packaging, and Composition
Metered-dose nasal spray in the form of a transparent, colorless or light yellow solution.
| 1 ml | 1 dose | |
| Human recombinant interferon alfa-2b | Not less than 10000 IU | Not less than 500 IU |
Excipients: disodium edetate dihydrate, sodium chloride, sodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, povidone, macrogol 4000, purified water.
10 ml (200 doses) – plastic bottles (1) with a dosing device – cardboard boxes.
![Grippferon® [Spray, Drops] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Grippferon® [Spray, Drops] 2")